CalciMedica (CALC) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed CalciMedica (CALC) over the past year, losing 56.5% versus a loss of 91.8%. CytoMed Therapeutics is the larger company by market cap ($10.5 million vs $8.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | GDTC |
|---|---|---|
| Share price | $1.29 | $0.8818 |
| Market cap | $8.81M | $10.52M |
| 1-day change | -0.77% | -6.68% |
| YTD return | -96.05% | -29.22% |
| 1-year return | -91.84% | -56.46% |
| EPS (TTM) | $-6.85 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.00 | $3.68 |
| 52-week low | $1.28 | $0.68 |
| Distance from 52-week high | -96.42% | -76.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +3775.97% | +371.76% |
| Average volume | 75.54K | 78.66K |
| Shares outstanding | 6.83M | 11.93M |
| Employees | 15 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDTC has outperformed CALC by 35.4 percentage points over the past year.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
CALC vs GDTC FAQ
Which is bigger, CalciMedica or CytoMed Therapeutics?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $10.52M compared with $8.81M for CalciMedica (CALC).
Which stock has performed better over the past year, CALC or GDTC?
GDTC returned -56.46% over the past 12 months, compared with -91.84% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are CalciMedica and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.